Core Viewpoint - C百奥 (688796) experienced a significant increase of 146.63% on its first trading day, with a turnover rate of 75.80% and a transaction volume of 1.671 billion yuan [2]. Company Overview - C百奥 specializes in gene editing technology, providing innovative model animals and preclinical pharmaceutical research services. The company utilizes its proprietary RenMice platform for large-scale drug discovery targeting over a thousand potential drug targets in humans [2]. - The company has developed into an enterprise with four technical platforms: gene-edited model animal preparation, innovative model animal breeding and supply, preclinical pharmacology and efficacy evaluation, and antibody drug discovery [2]. Financial Performance - On its first trading day, C百奥 had a financing buy-in amount of 123 million yuan, accounting for 7.39% of the total trading volume, with a latest financing balance of 111 million yuan, representing 4.72% of the circulating market value [2]. - The stock attracted a net inflow of 765 million yuan from major funds, with large single orders contributing 428 million yuan and big orders contributing 337 million yuan [2].

Group 1 - The company N Bai Ao (688796) was listed today, opening with a rise of 117.39%, and by midday, the increase expanded to 135.38% with a trading volume of 20.49 million shares and a turnover of 1.244 billion yuan, resulting in a turnover rate of 57.10% [2][3] - The company specializes in providing innovative model animals and preclinical pharmaceutical research and development services based on its self-developed gene editing technology, utilizing its RenMice platform for large-scale drug discovery and development targeting over a thousand potential drug targets in the human body [2] - After over a decade of development, the company has established itself with four technical platforms: gene-edited model animal preparation, innovative model animal breeding and supply, preclinical pharmacology and efficacy evaluation, and antibody drug discovery, aiming to provide high-quality products and services for new drug development [2] Group 2 - The total number of shares issued by the company is 47.5 million, with an online issuance of 11.461 million shares at a price of 26.68 yuan per share, resulting in an issuance price-to-earnings ratio of 519.12, compared to the industry average of 39.31 [3] - The final online issuance success rate was 0.02801388%, and the total fundraising amount from the initial public offering (IPO) is 1.267 billion yuan, primarily directed towards early drug development service platform construction, working capital supplementation, preclinical and clinical research projects, and antibody drug research and evaluation projects [3]

Group 1 - The core viewpoint of the article highlights the successful listing of N百奥, with an opening price of 58.00 yuan, reflecting a significant increase of 117.39% on its first trading day [2] - The company specializes in gene editing technology, providing innovative model animals and preclinical pharmaceutical research services, utilizing its proprietary RenMice platform for large-scale drug discovery and development [2] - N百奥 has developed into a comprehensive enterprise over the past decade, focusing on gene-edited model animal production, innovative model animal breeding, preclinical pharmacology and efficacy evaluation, and antibody drug discovery [2] Group 2 - The total issuance of shares for N百奥 was 47.50 million, with an online issuance of 11.46 million shares at a price of 26.68 yuan per share, resulting in a high issuance price-to-earnings ratio of 519.12, compared to the industry average of 39.31 [3] - The effective subscription number for the online issuance reached 6.03 million households, with a final winning rate of 0.02801388% [3] - The funds raised, totaling 1.267 billion yuan, will primarily be allocated to early drug development service platform construction, working capital, preclinical and clinical research projects, and antibody drug research and evaluation projects [3]

1.4980D ，a。 科创板投资风险提示：本次股票发行后拟在科创板市场上市，该市场具有较高的投 资风险。科创板公司具有研发投入大、经营风险高、业绩不稳定、退市风险高等特 点，投资者面临较大的市场风险。投资者应充分了解科创板市场的投资风险及本公 司所披露的风险因素，审慎作出投资决定。 百奥赛图（北京）医药科技股份有限公司 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. （北京市大兴区中关村科技园区大兴生物医药产业基地宝参南街 12 号院） 首次公开发行股票并在科创板上市 招股说明书 保荐人（主承销商） 百奥赛图（北京）医药科技股份有限公司 招股说明书 声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对注册申请文 件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈利能力、 投资价值或者对投资者的收益作出实质性判断或保证。任何与之相反的声明均属虚假不 实陈述。 根据《证券法》的规定，股票依法发行后，发行人经营与收益的变化，由发行人自 行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担股票依法发 行后因发行人经营与收 ...

Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. is focused on innovative drug development and aims to enhance its capabilities through an IPO on the Sci-Tech Innovation Board, raising approximately 1.185 billion RMB for various projects [9][10][35]. Company Overview - Baiaosaitu is an innovative preclinical CRO and biotechnology company established in 2009, specializing in gene editing technology and providing various preclinical drug development services [12]. - The company has developed four major technology platforms: gene-edited model animal preparation, innovative model animal breeding and supply, preclinical pharmacology and efficacy evaluation, and antibody drug discovery [7][12]. Business Model and Services - The company addresses two core challenges in antibody drug development: obtaining high-quality antibody molecules and the lack of precise evaluation models [8]. - Baiaosaitu has created a comprehensive human antibody library and a humanized mouse library, enabling the discovery of antibody candidates against over 1,000 potential drug targets [8][16]. - The company has established partnerships with top global pharmaceutical companies, enhancing its credibility and accelerating its international business expansion [8][14]. Financial Overview - The company expects to raise 1.185 billion RMB through its IPO, which will be used for upgrading early drug development service platforms, antibody drug research, and enhancing preclinical research projects [9][35]. - The company's main business revenue has shown a compound annual growth rate of 35.56% over the past three years, with revenues of approximately 533.36 million RMB, 716.40 million RMB, and 980.07 million RMB in recent years [22]. Future Development Plans - The company plans to continue promoting its "Thousand Mice and Ten Thousand Antibodies" initiative, aiming to discover novel antibody candidates for external collaboration or internal development [24]. - Baiaosaitu intends to expand its preclinical product and service offerings, particularly in oncology, autoimmune diseases, cardiovascular, metabolic, and neurological disorders [24][25]. - The company aims to establish extensive partnerships with leading pharmaceutical and biotechnology companies both domestically and internationally [25]. Competitive Advantages - The company possesses leading gene editing technology, a comprehensive range of model animals, and a significant first-mover advantage in antibody development [27]. - The unique "Thousand Mice and Ten Thousand Antibodies" plan provides flexibility in research, collaboration, and business models, enhancing its competitive edge [27]. Regulatory and Market Position - Baiaosaitu has received AAALAC certification, ensuring compliance with international standards for laboratory animal care [20]. - The company meets the listing standards for the Sci-Tech Innovation Board, with an expected market value of no less than 3 billion RMB and recent annual revenue exceeding 300 million RMB [32].

Investment Rating - The investment rating for the company is positioned in the mid-to-lower range, with an AHP score of 2.38, placing it in the 38.9% percentile of the overall score [2][5]. Core Insights - The company, Baiaosaitu, is a leading preclinical CRO and biotechnology firm, focusing on gene editing, model animal sales, preclinical pharmacology and efficacy evaluation services, and antibody development. The gene editing technology is a significant foundation for its business, having developed proprietary CRISPR/EGE technology that enhances gene editing efficiency by nearly 20 times, significantly reducing commercial application costs [2][12]. - The company has expanded its business into innovative model animal sales, having developed over 4,300 gene-edited animals and cell models, including more than 1,700 humanized mice. The establishment of a production center compliant with AAALAC international standards supports large-scale breeding and supply of model animals [12][30]. - The company has established a comprehensive pharmacology and efficacy evaluation system, serving approximately 950 partners globally and completing over 6,350 drug evaluation projects. It has collaborations with 9 of the top 10 global pharmaceutical companies in the pharmacology and efficacy sector [2][18]. Summary by Sections AHP Score and Expected Allocation Ratio - The AHP score for Baiaosaitu is 2.38, indicating a mid-to-lower performance level in the AHP model [5][6]. Company Fundamentals and Highlights - Baiaosaitu has built platforms for gene editing, model animal breeding, preclinical pharmacology evaluation, and antibody drug development, evolving from a single-service biotechnology company to a leading biopharmaceutical enterprise [6][12]. - The company’s revenue composition shows that model animal sales accounted for approximately 44% of total revenue in the first half of 2025, followed by antibody development and preclinical pharmacology services [7][8]. Financial Comparison with Peers - From 2022 to the first half of 2025, Baiaosaitu's revenue was lower than that of comparable companies, with revenues of 5.34, 7.17, 9.80, and 6.21 billion yuan respectively. However, the net profit turned positive in 2024, with a net profit margin that improved over time [22][24]. - The company’s gross margin was relatively high, with figures of 73.38%, 70.59%, 77.67%, and 74.39% from 2022 to the first half of 2025, outperforming the average of comparable companies [24][25]. Fundraising Projects and Development Vision - The company plans to raise funds for projects including the construction of a drug early research service platform, antibody drug research and evaluation projects, and preclinical research projects, which are expected to enhance its core competitiveness and solidify its industry position [30][31].

Core Viewpoint - The company, BaiOsaite (688796.SH), has announced its initial public offering (IPO) on the Sci-Tech Innovation Board, planning to issue 47.5 million shares, which represents 10.63% of the total share capital post-issue [1] Group 1: Company Overview - Established in 2009, the company operates as a preclinical Contract Research Organization (CRO) and biotechnology firm, focusing on gene editing technology to provide innovative model animals and preclinical drug development services [1] - The company has developed the RenMice platform, which includes various series of fully human antibodies/TCR mice, aimed at large-scale drug discovery targeting over a thousand potential drug targets [1] - The company has evolved into a comprehensive entity with four technical platforms: gene-edited model animal preparation, innovative model animal breeding and supply, preclinical pharmacology and efficacy evaluation, and antibody drug discovery [1] Group 2: Business Performance - As of the reporting period, the company has completed approximately 5,300 customized gene editing projects and developed over 4,300 types of gene-edited animals and cell line models [2] - The company’s innovative model animals and cell products include humanized mouse models targeting immune checkpoints and cytokines, severe immunodeficient mice, various spontaneous disease models, and human-derived cell lines, covering areas such as tumors, autoimmune diseases, metabolism, and neurology [2] - The company's main business revenues for the reporting periods were 533 million yuan, 716 million yuan, 980 million yuan, and 621 million yuan, with a compound annual growth rate of 35.56% from 2022 to 2024 [2] Group 3: Fundraising and Investment Plans - The funds raised from the IPO, after deducting issuance costs, will be allocated to several projects in order of priority: early drug development service platform construction, antibody drug research and evaluation, preclinical research projects, and supplementing working capital, with a total investment amount of 1.185 billion yuan [3]

Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. has been approved for IPO by the Shanghai Stock Exchange, marking it as the 53rd company to pass this year, with a focus on innovative drug development services based on its proprietary gene-editing technology [1]. Company Overview - Baiaosaitu was established in 2009 and operates as a preclinical CRO and biotechnology company, providing various innovative model animals and preclinical drug development services [1]. - The company utilizes its self-developed RenMice platform for large-scale drug discovery and development, targeting over a thousand potential drug targets in the human body [1]. IPO Details - The company plans to issue up to 99,849,605 shares on the Sci-Tech Innovation Board, with a minimum public offering ratio of 10% of the total share capital post-issuance [2]. - The intended fundraising amount is 118.504 million yuan, aimed at building a drug early-stage research service platform, antibody drug research and evaluation projects, preclinical research projects, and supplementing working capital [2]. Shareholding Structure - As of the signing date of the prospectus, the actual controllers of Baiaosaitu, Shen Yulei and Ni Jian, collectively control 27.0291% of the voting rights [2]. Market and Business Model Inquiry - The listing committee inquired about the technological advancement of the fully human antibody mouse platform, market space for antibody development, and the stability and future profitability of the business model, including revenue realization from project testing to transfer/authorization/co-development [3].

Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. is set to return to A-share market after successfully passing the listing review by the Shanghai Stock Exchange, marking its A+H listing strategy [1] Group 1: Company Overview - Baiaosaitu, established in 2009, is a preclinical CRO and biotechnology company that provides innovative model animals and preclinical drug development services based on its proprietary gene editing technology [1] - The company has developed a comprehensive platform that includes gene-edited model animal preparation, innovative model animal breeding and supply, preclinical pharmacology and efficacy evaluation, and antibody drug discovery [1] Group 2: Business Achievements - As of the reporting period, Baiaosaitu has completed over 5,100 customized gene editing projects and developed more than 3,500 types of RenMice and other gene-edited animals and cell line models [2] - The company has established partnerships with numerous renowned biotech and pharmaceutical companies for antibody drug discovery, leveraging its RenMice platform and "thousands of mice, ten thousand antibodies" approach [2] Group 3: Financial Performance - From 2022 to 2024, Baiaosaitu's revenue is projected to be 534 million yuan, 717 million yuan, and 980 million yuan, with a compound annual growth rate of 35.56% [3] - The net profit for the same period is expected to be -602 million yuan, -383 million yuan, and 33.54 million yuan, indicating a turnaround to profitability in 2024 [3] Group 4: IPO and Fundraising - Baiaosaitu plans to raise 1.185 billion yuan through its IPO, which will be directed towards enhancing its existing business and core technologies [3] - The fundraising will support projects aimed at expanding the production capacity of model animals, improving early drug discovery capabilities, and enriching the preclinical research pipeline [3]